【摘要】 1988年6月～1992年1月经导管肝动脉灌注化疗及栓塞术治疗不能切除的原发性肝癌70例,男64例,女6例.年龄23岁～66岁,中位年龄47.6岁.Ⅱ期57例,Ⅲ期13例.采用Seldinger氏插管法.治疗方式分3种:TAI、LP—TAE及LP+GS-TAE.经治疗80％病人临床症状改善,疼痛减轻或消失,肿瘤缩小.67.6％病人AFP降低或转阴.生存期延长,半年、1年、2年及3年总生存率分别为62.1％(41/66)、42％(21/50)、34.6％(9/26)及31.6％(6/19).研究表明LP十GS-TAE对不能手术切除的肝癌患者应作为首选疗法.更多还原

【Abstract】 Seventy patients with unresectablc primary liver cancer were treated with transcatheter hepatic artery infusion and embolization during the period from June 1988 to January 1992. 64 patients were males and 6 females and aged 23-66 years(mean47. 6 years). Fifty-seven cases of this series were of stage Ⅱ disease and 13 stage Ⅲ. Seldinger needle was used to insert the catheter in the femoral artery. In 80% of the patients symptoms and pains were ameliorated and tumor size reduced after treatment. In 67. 6% of cases,AFP values were either declined or turned negative. The duration of survival were prolonged and the survivals for 6 months and 1, 2and3years rated 62. 1% (41/66), 42% (21/50), 34. 6%(9/26), 31. 6%(6/19)respectively. The findings demonstrated that TAE with lipoidol and jelly foam plus chemotherapeutic agent is a good choice for palliative treatment in patients with unresectable hepatic carcinoma.更多还原